Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03737838 · ClinicalTrials.gov registry record
Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 29
- Enrollment target
NCT03737838: Completed study, sponsored by University of Chicago.
NCT03737838 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03737838 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to perform ultra-high density mapping of the left atrium (a chamber of the heart) using the the Rhythmia Mapping System and to determine whether additional ablation in areas of wavefront discontinuities identified by the map will reduce the likelihood of both atrial fibrillation and atrial flutter.
Primary Outcome
Freedom from atrial arrhythmias
Interventions
- DEVICE Atrial fibrillation ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2021-02-24 |
What the finished NCT03737838 record still lists
NCT03737838 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Atrial fibrillation ablation is the first listed.
NCT03737838 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03737838 about?
NCT03737838 is a clinical study titled "Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)". The purpose of this study is to perform ultra-high density mapping of the left atrium (a chamber of the heart) using the the Rhythmia Mapping System and to determine whether additional ablation in areas of wavefront discontinuities identified by the map will reduce the likelihood of both atrial fibr...
What is the current status of trial NCT03737838?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2018-10-31. Estimated completion is 2021-02-24.
What interventions are being tested in trial NCT03737838?
The interventions under investigation include: Atrial fibrillation ablation (DEVICE).
Who is sponsoring clinical trial NCT03737838?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI